Cancer, Malaria & TB Vaccines
Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovale. P. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.
Related Conference of Cancer, Malaria & TB Vaccines
7th World Congress on Neuroimmunology and Neuroinfectious Diseases
Cancer, Malaria & TB Vaccines Conference Speakers
Recommended Sessions
- Animal & Plant Derived Vaccines
- Animal Models & Clinical Trials
- Antibodies: Engineering & Therapeutics
- Cancer, Malaria & TB Vaccines
- Cellular Immunology & Latest Innovations
- Combination & Conjugate Vaccines
- Current Research & Future Challenges
- DNA & Synthetic Vaccines
- Fish & Poultry Vaccines
- Geriatric Immunization
- HIV Vaccines
- Paediatric Vaccination
- Travel & Edible Vaccines
- Vaccine Production & Development
- Vaccine Safety & Efficacy
- Vaccines & Autism
- Vaccines against Drugs‎
- Vaccines against Infectious Diseases
- Vaccines for Immune Mediated Diseases
- Vaccines for Pregnant Women & Neonates
- Vaccines for Unconventional Diseases
- Vectors, Adjuvants & Delivery Systems
Related Journals
Are you interested in
- Advances in Neuroimaging and Diagnostic Techniques - Neuroimmunology Congress 2026 (France)
- Advances in Neuroimmunology and Neuroinflammation - Neuroimmunology Congress 2026 (France)
- Artificial Intelligence and Data-Driven Approaches in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Autoimmune Neurological Disorders and Therapeutic Advances - Neuroimmunology Congress 2026 (France)
- Biomarkers and Precision Medicine in Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Case Studies and Clinical Practice in Neuroimmunology and Neuroinfectious Diseases - Neuroimmunology Congress 2026 (France)
- Clinical Trials and Drug Development in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- CNS Infections: Diagnosis, Management, and Prevention - Neuroimmunology Congress 2026 (France)
- Emerging Technologies and Future Directions in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Ethical Considerations and Future Perspectives in Neuroimmunology Research - Neuroimmunology Congress 2026 (France)
- Immunogenetics and Neuroimmune Interactions - Neuroimmunology Congress 2026 (France)
- Immunotherapy and Novel Treatment Strategies - Neuroimmunology Congress 2026 (France)
- Microbiome and the Gut-Brain-Immune Axis - Neuroimmunology Congress 2026 (France)
- Neurodegeneration and Immune System Interactions - Neuroimmunology Congress 2026 (France)
- Neuroimmunology in Pediatric Disorders - Neuroimmunology Congress 2026 (France)
- Neuroinfectious Diseases and Global Health Challenges - Neuroimmunology Congress 2026 (France)
- Public Health, Policy, and Global Collaboration in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Rehabilitation and Long-Term Management of Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Translational Research and Clinical Applications in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Young Researchers, Innovation, and Emerging Ideas - Neuroimmunology Congress 2026 (France)
